Form 4: Imunon Director James E. Dentzer Acquires Stock Options

Director James E. Dentzer acquired stock options in Imunon, Inc. on June 12, 2024.

Summary

• On June 12, 2024, James E. Dentzer, a director of Imunon, Inc., acquired stock options to purchase 4,500 shares of common stock at an exercise price of $1.22 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• Following the transaction, Dentzer directly owns 13,667 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative news.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Imunon, Director, Stock Options, Beneficial Ownership, Form 4, IMNN, Securities